KROS
Keros Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$10.94
+1.06%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$11.22
From 52W high−49.89%
Volume60976.00
Market cap$217.00M
P/E (TTM)—
P/S (TTM)14.5x
Div yield—
Key dataNov 4, 2026
Open
$11.22
From 52W high
−49.89%
Volume
60976.00
Market cap
$217.00M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.3x
P/E (TTM)
—
RSI (14)
44.3
MomentumView details →
1D Return
+1.06%
YTD Return
−46.54%
SummaryUpdated Jun 1, 2026
Keros Therapeutics, Inc. (NASDAQ:KROS) is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in Lexington, Massachusetts. The company went public in April 2020 and focuses on developing novel treatments for patients with hematological and musculoskeletal disorders that have significant unmet medical needs. Keros operates in the specialized field of protein therapeutics and small molecule drugs, targeting conditions affecting blood cell production and bone health.
Similar companies
Latest newsMore news →
Keros Therapeutics dosed the first patient in a Phase 2 clinical trial of rinvatercept in patients with Duchenne muscular dystrophy.37d agoKeros Therapeutics' board approved a $5 million share repurchase program of its common stock, following receipt of a $20 million development milestone payment from Takeda Pharmaceuticals under the elritercept license agreement.57d agoKeros Therapeutics will receive a $20 million development milestone payment from Takeda after the first patient was dosed in the ELRiSE MDS clinical trial.97d ago